Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of depolymerized holothurian glycosaminolycan in preparation of medicine for preventing and treating thromboembolism diseases

一种糖胺聚糖、血栓栓塞的技术，应用在解聚海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用领域，能够解决抗凝药物安全隐患、给药方式繁复、安全隐患等问题，达到有利于药物使用、显著抗凝血作用、递增趋势缓和的效果

Active Publication Date: 2013-09-11
SHANGHAI KAIRUN BIOLOGY MEDICINE LIMITED LIABILITY +1
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are many kinds of anticoagulant drugs available, but most of them are western anticoagulant drugs with relatively large side effects. When using them, the blood coagulation status needs to be checked repeatedly to avoid bleeding. In addition, the administration methods are complicated. Drugs are a safety hazard
For example, currently widely used anticoagulant drugs such as heparin, low-molecular-weight heparin, and warfarin need to detect blood coagulation status during use. Excessive use or use by people with different physiques can easily cause various bleedings, posing serious safety risks.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of depolymerized holothurian glycosaminolycan in preparation of medicine for preventing and treating thromboembolism diseases
  • Application of depolymerized holothurian glycosaminolycan in preparation of medicine for preventing and treating thromboembolism diseases
  • Application of depolymerized holothurian glycosaminolycan in preparation of medicine for preventing and treating thromboembolism diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Extraction of sea cucumber glycosaminoglycans:

[0030] Weigh 5 kg of Yuzu sea cucumber medicinal material and soak in water overnight. Drain the body wall of the sea cucumber, mince it, weigh it and add water to 40Kg, put it in a water bath at 60°C, add 6mol / L sodium hydroxide to adjust the pH to 8.0±0.2, add 100ml of protease Alcalase (Novozymes (Shenyang) Biotechnology Co., Ltd.) stirring, enzymatic hydrolysis for 4 hours, inactivation above 85°C for 10 minutes, cooling to 50°C±2°C, adding 6mol / L sodium hydroxide to adjust the pH to 8.0±0.2, and adding 10g of compound trypsin (Wuxi City Xuemei Enzyme Preparation Technology Co., Ltd. (Xuemei Brand) stirred for 4 hours, boiled for 10 minutes, and cooled. Centrifuge at 4°C, collect the supernatant, add 6mol / L hydrochloric acid to adjust the pH to 2.5±0.2, refrigerate at 4°C for 2 hours, centrifuge, collect the supernatant, add 6mol / L sodium hydroxide to adjust the pH to 7.0±0.2, add 0.8 double ethanol, and let stand o...

Embodiment 2

[0041] Pharmacodynamic experiment of depolymerized sea cucumber glycosaminoglycan

[0042] 2.1 In vitro anticoagulation experiment

[0043] 2.1.1 Test material

[0044] Samples for testing:

[0045] Name: depolymerized sea cucumber glycosaminoglycan (26,000Da~45,000Da), the following abbreviation: DHG;

[0046] Source: Shanghai Korrun Biomedical Co., Ltd.;

[0047] Batch number: 20110308;

[0048] Preparation: Dilute with normal saline for injection to the required concentration after precision drawing.

[0049] experimental animals

[0050] Strain: Rabbit;

[0051] Source: Shanghai Chenxing Experimental Rabbit Co., Ltd.;

[0052] Gender: Male;

[0053] Weight: 1800 grams;

[0054] Animal certificate number: SCXK (Shanghai) 2007-0010.

[0055] 2.1.2 Test equipment

[0056] Platelet aggregation coagulation factor analyzer (model LG-PABER Beijing Shidi Scientific Instrument Company).

[0057] 2.1.3 Experimental method

[0058] On the day of the experiment, add 80 μl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of depolymerized holothurian glycosaminolycan in preparation of a medicine for preventing and treating thromboembolism diseases. The depolymerized holothurian glycosaminolycan is more than one of depolymerized holothurian glycosaminolycan with weight-average molecular weight of 26000Da-45000Da. In intravenous injection or subcutaneous injection of the medicine utilizing the depolymerized holothurian glycosaminolycan with weight-average molecular weight of 26000Da-45000Da as an active ingredient, the medicine has excellent anticoagulation effect and small side effect, thereby being capable of being effectively used for preventing and treating thromboembolism diseases. With dosage increase, the blood coagulation time of the injection of the depolymerized holothurian glycosaminolycan with weight-average molecular weight of 26000Da-45000Da is prolonged and the anticoagulation effect is enhanced, and the medicine is dosed by subcutaneous injection to better facilitate the medicine utilization and improve the medicine utilization convenience and security at the same time.

Description

technical field [0001] The invention relates to a medical application of depolymerized sea cucumber glycosaminoglycan, in particular to the application of depolymerized sea cucumber glycosaminoglycan with a weight average molecular weight of 26,000Da to 45,000Da in the preparation of medicines for preventing and treating thromboembolic diseases, including arterial Atherosclerotic thrombotic diseases and venous thromboembolic diseases, as well as the application of anti-thrombotic drugs after surgery. Background technique [0002] The blood viscosity of middle-aged and elderly people often gradually increases, and the possibility of platelet aggregation leading to thrombus (such as coronary artery and cerebral artery) increases. Thromboembolic disease has become a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people. disease. Thrombosis is the main cause of arterial diseases such as myocardial infarction and stroke, as...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/726A61P7/02A61P9/00
CPCA61K9/0019A61K9/19A61K31/7028A61K31/726A61K35/616A61P7/02A61P9/00C08B37/0063C08B37/0066C08B37/0069
Inventor 王志国刘全海董玉琼
Owner SHANGHAI KAIRUN BIOLOGY MEDICINE LIMITED LIABILITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com